FDA Set to Approve Earlier Use of CAR T for Multiple Myeloma

The treatment is currently approved for patients who fail four lines of treatment

Moffitt Expands TIL Therapy Research to Sarcoma Patients

Young sarcoma patients may benefit from tumor infiltrating lymphocyte therapy.

New Breakthrough Therapy for Metastatic Melanoma Receives FDA Approval

The personalized therapy uses a patient’s own immune cells to recognize and fight cancer

CAR T Effective as First-Line Therapy for High-Risk Lymphoma Patients

New three-year data from the phase 2 ZUMA-12 trial finds durable responses

FDA Investigating ‘Serious Risk’ of Malignancy After CAR T Therapy

Benefits of the treatment still outweigh its risks, experts say

Bioengineering: A New Frontier in Cancer Research

The launch of Moffitt’s Bioengineering Department brings novel tools to the fight against cancer

Moffitt Study Aims to Improve Personalized Cancer Vaccines

Selection of neoantigen target critical to therapy’s success

New Approach Using mRNA Generates Cellular Immunotherapy Within the Body

In vivo CAR macrophage therapy can be used to treat solid tumors

Are Cellular Therapies the New Frontier in Cancer Treatment?

Moffitt experts discuss the latest in cellular therapy at annual Research Innovation event

Endeavor